Home > Insider Trading > Filing (0001209191-17-002805)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1437786	Immune Design Corp.	IMDZ	Pharmaceutical Preparations (2834)	262007174

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1606244	V Carlos Paya	C/O Immune Design Corp. 1616 Eastlake Ave. E., Suite 310 Seattle WA 98102	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-01-04	36,000	$0.00	72,000	No	4	A	Direct
Common Stock	Disposition	2017-01-04	3,940	$5.35	68,060	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2017-01-04	175,000	$0.00	175,000	$5.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
175,000		2027-01-04	No	4	A	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
One quarter of the total restricted stock units vest annually beginning January 4, 2018, subject to the Reporting Person's continuous servicethrough each such date.
The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2016, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2017.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
One quarter of the shares underlying the option will vest on January 4, 2018, and the remainder of the shares underlying the option will vest at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date.